Life Sciences 4.0: securing value through data-driven platforms: Recent Episodes
Matthew Elliott
In Life Sciences 4.0: securing value through data-driven platforms, we explore how health is being reimagined because of scientific and technological change and rising customer expectations. We also examine the ramifications for life sciences companies’ market offerings, business models and the new capabilities needed as the disciplines of health care and technology merge to become “health technology”.
Read more by visiting us at www.ey.com/lifesciences
There are 2,600 cell and gene therapy clinical trials taking place this year. In the US alone, this could translate up to 20 new therapy approvals in 2022, which presents a clear opportunity to make more life-saving therapies available to a greater number of individuals. In this podcast, Adlai Goldberg, Global Digital, Social and Commercial Innovation Life Sciences Leader for EY, talks to Tamie Joeckel – ICON’s Cell and Gene Therapy Global Business Lead, as they discuss what makes an increase in the volume of trials and an acceleration of the clinical trial process significant.
In the first EY Pointellisä Podcast, Adlai Golderg, Dr. Yele Aluko, EY Chief Medical Officer, and Dr. David Rhew, Microsoft Chief Medical Officer, explore and frame the health equity challenges the world is facing today. Addressing health care inequality is a global challenge. For Dr. Yele Aluko, EY Chief Medical Officer, and Dr. David Rhew, Microsoft Chief Medical Officer, finding opportunities to provide health equity is a shared passion. Both are experienced physicians, and in this podcast, we discuss why disparities exist, the root causes and unbiased digital solutions. Health care disparity doesn’t begin at the time of diagnosis and treatment – it goes back further to clinical trials and the fact that low enrolment rates of minorities would generate results that were not reflective of the populations. And while COVID-19 has both given rise to a groundswell of societal demand for equal treatment for all people, the pandemic has also highlighted the health disparities across populations. The way forward requires strategic insight from the health care value chain. Using data and analytics to not only identify care gaps – but to then develop the tactics and solutions that will close them. Microsoft is building technologies that can be used by millions to make things easier, with usability a key factor. Barriers such as lack of broadband, or physical disabilities such as poor vision and hearing, must be overcome. Dr. Aluko and Dr. Rhew see health equity is an important mission, because achieving it means everyone has a better chance of fulfilling their life’s potential.
In this episode of Pointellis, Adlai Goldberg explores the life-changing world of cancer diagnosis and the path to full remission with Asaf Adler, Operations Senior Manager with EY. Asaf Adler, EY Americas Senior Manager for Consulting, Business Consulting, Supply Chain & Operations, faced among the hardest patient challenges imaginable: stage 4 melanoma and lung cancer. But, today, as a cancer survivor, he’s optimistic about the state of cancer treatments. In this podcast, Adlai Goldberg, EY Social and Commercial Innovation Life Sciences Leader, speaks with Asaf about his experience finding out he had cancer to his discovery of individual-targeted treatments, his journey to remission and overall advancements in the life science sector. Summer 2021 is a milestone in cancer treatment, as Phase 2 of the mRNA cancer vaccine (BioNTech) is introduced to its first patient. Asaf and Adlai share their excitement and hope around this amazing era of hope for cancer treatment. Asaf’s own remarkable story underscores how quickly the clinical science is advancing and the profound impact these treatments have not only on the lives of current patients, but also to the loved ones surrounding them.
In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of “Health Experience.” The Health Sciences and Wellness industry has never been as “front and center” in our lives as it has been in this last year. As all of us, worldwide, ride the various waves of the pandemic, our Health Sciences and Wellness industry has taken the lead in giving care to those who have needed it most. We have also seen a monumental collaborative R&D effort – at a scale never witnessed before – which has resulted in the creation and delivery of multiple approved vaccines to combat the virus. Companies have an opportunity to seize this inflexion point, because the reality (as we have seen with other industries) is that products or services alone, no matter how strong technically will not be enough in future.
The COVID-19 pandemic provides the ‘burning platform’ for accelerating the data agenda. While companies and organizations long recognized the potential of new tools to capture and use data to transform health, they lacked the “burning platform” to fuel this change. The COVID-19 pandemic and the global disruption it caused has demonstrated that organizations can become more resilient, agile and innovative if they shift to digitally enabled business models with data at the core.
New technologies are creating new opportunities, but they are also creating unknown and unquantified risks. Organizations that understand what it takes to succeed with new cost and revenue models, new value propositions, and new relationships with the right partners, will start to reshape the health market. In this edition of New Horizons, we explore four areas where this process of reshaping is underway.
With dealmaking a cornerstone of the growth strategy, 2020 will be a robust year for life sciences M&A. To succeed, companies must continue to focus their business models, close near term growth gaps and invest in future innovation.
In the EY 2019 Pulse of the industry, we review the performance of the global medical technology industry. The industry continues to grow, but its long-term outlook is at risk from underinvestment in R&D and lack of collaboration between industry providers, payers and patients.
Nothing can change if minds do not. How can we make common ground the foundation for real change? As technology increasingly takes on the role of management, more emphasis falls on the role of leaders. Neuroscience is uncovering approaches to influence that leaders can use to enlist others to share their beliefs and commitments. In this episode of The Better Question, EYQ Fellow Chris Meyer is joined by Tali Sharot, professor of cognitive neuroscience at University College London and EYQ Fellow, and Seth Godin, entrepreneur and author of numerous bestsellers, including Permission Marketing: Turning Strangers into Friends and Friends into Customers.
Data is the driving force underpinning the Fourth Industrial Revolution and the emergence of new business models. In health care, the goal is to use data to deliver interventions more proactively and in more personalized ways, ultimately leading to better health outcomes and a shift to prevention. Five trends are leading the rise of a new, data-centric approach to health care. An organization’s ability to generate value depends on how effectively it can unlock the power of data and generate insights by connecting, combining and securely sharing data at greater scale than ever before. Learn more by visiting us at ey.com/lifesciences
Over the past three decades, life sciences companies have used their biological and chemical know-how to create significant value for themselves, their shareholders and most importantly patients. In today’s fast-changing environment, it’s very likely that life sciences companies will need access to an array of medical and non-medical data to demonstrate value to their stakeholders. In the latest 2019 EY M&A Firepower report, we explore the dealmaking strategies life sciences should prioritize to generate growth. This year’s findings show that life sciences companies must accelerate their agendas on the creation of focused business models and the acquisition of disruptive, digital capabilities. Learn more by visiting us at ey.com/firepower.
An EY study shows that data and digital are transforming the life sciences industry. Hear from leaders how industry players can seize the upside of this disruption, and what it means for patient-consumers.
In EY Pulse of the industry, we examine the annual performance of the medical device industry in the context of the technological advances and rising customer expectations associated with the Fourth Industrial Revolution. To thrive in this transformative age, medtechs must adapt their business models to meet the increased expectations of consumers and other health stakeholders. Read more by visiting www.ey.com/pulse